早期回盲部切除术治疗克罗恩病与抗肿瘤坏死因子治疗相比与长期结局改善相关:一项基于人群的队列研究
该研究利用全国联动登记数据,纳入2003至2018年诊断后1年内接受回盲部切除术或抗TNF治疗的回肠或回盲部克罗恩病患者1279例,比较长期结局。结果显示回盲部切除术组复合结局风险较抗TNF组低33%(aHR 0.67,95%CI 0.54-0.83),但作者指出观察性数据存在固有偏倚,需谨慎解读。
要点
- 早期回盲部切除术较抗TNF治疗与复合结局风险降低33%相关(aHR 0.67,95%CI 0.54-0.83)。
- 回盲部切除术与全身性糖皮质激素暴露和克罗恩病相关手术风险降低相关,其他次要结局无此关联。
- 术后5年免疫调节剂、抗TNF、后续切除及无治疗比例分别为46.3%、16.8%、1.8%、49.7%。
核心结论
- 这些数据提示回盲部切除术可能作为克罗恩病管理的一线治疗发挥作用,并挑战当前将手术保留用于复杂或药物难治/不耐受克罗恩病的范式。
- 鉴于观察性数据固有的偏倚,作者认为这些发现应谨慎解读并应用于临床决策。
研究设计与样本
- 基于全国联动登记数据的基于人群的队列研究。
- 纳入2003至2018年诊断的16,443例回肠或回盲部克罗恩病患者中,于诊断后1年内接受回盲部切除术或抗TNF治疗且符合入选标准的1279例个体。
- 其中45.4%接受回盲部切除术,54.6%接受抗TNF治疗。
- 采用校正Cox比例风险回归分析,并确定不同治疗后的累积风险。
主要发现
- 复合结局在回盲部切除术组发生273例(发生率110/1000人年),在抗TNF组发生318例(发生率202/1000人年)。
- 回盲部切除术组复合结局风险较抗TNF组低33%(校正风险比0.67;95%置信区间0.54-0.83)。
- 回盲部切除术与全身性糖皮质激素暴露和克罗恩病相关手术风险降低相关,但与其他次要结局无关。
- 回盲部切除术后5年时,使用免疫调节剂、使用抗TNF、接受后续切除及无治疗的比例分别为46.3%、16.8%、1.8%和49.7%。
临床怎么用
- 作者认为这些数据提示回盲部切除术可能作为克罗恩病管理的一线治疗发挥作用,并挑战当前将手术保留用于复杂或药物难治/不耐受克罗恩病的范式。
- 作者指出鉴于观察性数据固有的偏倚,这些发现应谨慎解读并应用于临床决策。
局限性
- 原文指出观察性数据存在固有偏倚,作者认为这些发现应谨慎解读并应用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Early Crohn's disease (CD) treatment involves anti-tumor necrosis factor (TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment failure. We compared long-term outcomes of primary ICR and anti-TNF therapy for ileocecal CD. METHODS: Using cross-linked nationwide registers, we identified all individuals diagnosed with ileal or ileocecal CD between 2003 and 2018 and treated with ICR or anti-TNF agents within 1 year of diagnosis. The primary outcome was a composite of ≥1 of the following: CD-related hospitalization, systemic corticosteroid exposure, CD-related surgery, and perianal CD. We conducted adjusted Cox's proportional hazards regression analyses and determined the cumulative risk of different treatments after primary ICR or anti-TNF therapy. RESULTS: Of 16,443 individuals diagnosed with CD, 1279 individuals fulfilled the inclusion criteria. Of these, 45.4% underwent ICR and 54.6% received anti-TNF. The composite outcome occurred in 273 individuals (incidence rate, 110/1000 person-years) in the ICR group and in 318 individuals (incidence rate, 202/1000 person-years) in the anti-TNF group. The risk of the composite outcome was 33% lower with ICR compared with anti-TNF (adjusted hazard ratio, 0.67; 95% confidence interval, 0.54-0.83). ICR was associated with reduced risk of systemic corticosteroid exposure and CD-related surgery, but not other secondary outcomes. The proportion of individuals on immunomodulator, anti-TNF, who underwent subsequent resection, or were on no therapy 5 years post-ICR was 46.3%, 16.8%, 1.8%, and 49.7%, respectively. CONCLUSION: These data suggest that ICR may have a role as first-line therapy in CD management and challenge the current paradigm of reserving surgery for complicated CD refractory or intolerant to medications. Yet, given inherent biases associated with observational data, our findings should be interpreted and applied cautiously in clinical decision making.
引用
- Agrawal M, Ebert AC, Poulsen G, et al. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study. Gastroenterology. 2023. PMID: 37321356. doi:10.1053/j.gastro.2023.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。